Wells Fargo & Company Immunity Bio, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 138,605 shares of IBRX stock, worth $419,973. This represents 0.0% of its overall portfolio holdings.
Number of Shares
138,605
Previous 106,271
30.43%
Holding current value
$419,973
Previous $394,000
10.15%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding IBRX
# of Institutions
229Shares Held
82.3MCall Options Held
1.02MPut Options Held
2.25M-
Vanguard Group Inc Valley Forge, PA17.3MShares$52.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$34.6 Million0.0% of portfolio
-
State Street Corp Boston, MA9.79MShares$29.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.01MShares$12.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.84MShares$11.6 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.21B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...